TROSPIUM CHLORIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Tropium chloride is a quaternary ammonium compound that acts as a competitive antagonist at muscarinic acetylcholine receptors (M1, M2, M3), thereby reducing smooth muscle tone in the bladder, decreasing detrusor overactivity, and increasing bladder capacity.
| Metabolism | Tropium chloride is minimally metabolized; the major metabolic pathway is ester hydrolysis, with the resulting dealkylated metabolite being pharmacologically inactive. It is primarily eliminated unchanged in urine and feces. |
| Excretion | Renal: 65% (40% unchanged, 25% as metabolites); Fecal/Biliary: 35% (primarily via bile) |
| Half-life | Terminal elimination half-life: 10-20 hours (mean 14 hours); clinical context: supports twice-daily dosing |
| Protein binding | 50–60% (primarily to albumin) |
| Volume of Distribution | 1.2–1.8 L/kg (indicates extensive tissue distribution) |
| Bioavailability | Oral: less than 10% (range 4–10%; due to extensive first-pass metabolism) |
| Onset of Action | Oral: 1–2 hours; peak effect 4–6 hours |
| Duration of Action | 12 hours (clinically relevant for overactive bladder dosing) |
20 mg orally twice daily, extended-release 60 mg orally once daily in the morning.
| Dosage form | TABLET |
| Renal impairment | Severe renal impairment (CrCl <30 mL/min): 20 mg orally once daily at bedtime; extended-release not recommended. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment; not studied in severe impairment. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Use with caution; increased sensitivity to anticholinergic effects; start at lowest effective dose. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other anticholinergic drugs can have additive effects Can cause blurred vision and urinary retention.
| Breastfeeding | Excreted in human milk in trace amounts; M/P ratio unknown due to low molecular weight. Likely compatible with breastfeeding due to low oral bioavailability, but monitor infant for anticholinergic effects (irritability, constipation). |
| Teratogenic Risk | FDA Pregnancy Category C. Animal studies show fetal harm at maternal toxic doses. First trimester: avoid unless benefit outweighs risk; limited human data. Second/third trimesters: risk of fetal anticholinergic effects (tachycardia, ileus); use only if clearly needed. |
■ FDA Black Box Warning
None.
| Common Effects | Dry mouth |
| Serious Effects |
["Urinary retention (absolute).","Gastric retention (absolute).","Uncontrolled narrow-angle glaucoma (absolute).","Hypersensitivity to the drug or any component."]
| Precautions | ["Use with caution in patients with bladder outflow obstruction due to risk of urinary retention.","May cause angioedema; discontinue if symptoms occur.","Can exacerbate symptoms of myasthenia gravis.","Use cautiously in patients with gastrointestinal obstructive disorders, ulcerative colitis, or impaired renal function (CrCl <30 mL/min).","May cause drowsiness or blurred vision; avoid driving or hazardous activities until effects are known."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal anticholinergic side effects (drowsiness, confusion, tachycardia, constipation). Fetal monitoring for growth and heart rate if used in third trimester. Assess for preterm labor symptoms due to potential smooth muscle relaxation. |
| Fertility Effects | Animal studies show no significant impairment of fertility at clinical doses. Human data limited; theoretical interference with cholinergic pathways in reproductive organs unlikely to affect fertility at therapeutic doses. |